Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

CXCL14 Enhances Myocyte Fusion and Activates the FAK-ERK5 Signaling Pathway in Skeletal Muscle Stem Cells and Myoblasts.

Created on 29 Jul 2026

Authors

Nurkyz Alymkulova, Younjeong Oh, Jennifer Fransisca, Bagus Sarmito, Yongsung Hwang, Jeong Kyo Yoon

Published in

International journal of stem cells. Jul 29, 2026. Epub Jul 29, 2026.

Abstract

Skeletal muscle regeneration is essential for maintaining muscle function throughout life and is regulated by numerous growth factors, cytokines and their associated signaling pathways. In this study, we investigated the role of C-X-C motif chemokine ligand 14 (CXCL14) in myogenic differentiation using skeletal muscle stem cells (MuSC) and the mouse myoblast C2C12 cell line. Notably, CXCL14 significantly enhanced myocyte fusion. To elucidate the underlying regulatory mechanisms, we examined fusion-associated signaling pathways and found that CXCL14 activates the focal adhesion kinase-extracellular regulated protein kinase 5 (FAK-ERK5) signaling pathway. Our findings identify the CXCL14-FAK-ERK5 signaling axis as a positive regulator of myocyte fusion. Furthermore, by establishing fibro-adipogenic progenitors (FAPs) as the primary source of CXCL14 and demonstrating its pro-fusion activity, this study provides new insight into the paracrine regulation from FAPs to MuSCs during muscle regeneration.

PMID:
42521489
Bibliographic data and abstract were imported from PubMed on 29 Jul 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 1
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement